Skeletal scintigraphy as an important complement for detecting bone metastasis from nasopharyngeal carcinoma

J Int Med Res. 2022 Aug;50(8):3000605221116765. doi: 10.1177/03000605221116765.

Abstract

Bone metastasis occurs frequently in patients with nasopharyngeal carcinoma (NPC). Although fluorine-18 fluorodeoxyglucose positron emission tomography with computed tomography (PET/CT) has been proven to be more sensitive at detecting bone metastases than Technetium-99m methylene diphosphonate skeletal scintigraphy in pretreatment patients with NPC in most clinical settings, there have been metastatic lesions that were positive on skeletal scintigraphy but negative on PET/CT scans. Herein, we report the case of a patient with stage IV NPC that manifested as multiple metabolically abnormal lesions on pretreatment skeletal scintigraphy and were considered malignant although they were negative on PET/CT examination. Follow-up evaluations with both skeletal scintigraphy and PET/CT scans as post-therapeutic imaging are also presented.

Keywords: Technetium-99m methylene diphosphonate; bone metastasis; case report; fluorodeoxyglucose positron emission tomography/computed tomography; nasopharyngeal carcinoma; skeletal scintigraphy.

Publication types

  • Case Reports

MeSH terms

  • Bone Neoplasms*
  • Fluorodeoxyglucose F18
  • Humans
  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Neoplasms*
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography
  • Radionuclide Imaging
  • Radiopharmaceuticals

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18